Hongtai Capital Holdings is a private equity and venture capital firm that specializes direct and fund of funds investments through Aplus Fund and Aplus Capital. It specializes in direct investments covering angel and growth capital stage investments in big data, artificial intelligence, financial technology, consumer upgrade, cultural entertainment, internet, internet of things, and intelligent manufacturing sectors for Aplus Fund Hongtai Capital specializes in direct and fund of funds investments through mature stage investments, acquisitions, and industry consolidation in healthcare, new healthcare, health, medical treatment, biotechnology, healthcare education, next generation health diagnostics, alternative energy, advanced manufacturing in Shandong Province in China for Aplus Capital. It prefers to invest in companies with IPO potential for Aplus Capital.  Hongtai Capital typically makes joint acquisitions and acquire majority stakes in portfolio companies for acquisitions. It seeks to exit though selling or injecting into listed companies for acquisition of majority stakes.  Hongtai Capital acquires minority stakes and prefers to exit through reorganization and listing. It also specializes in incubation, seed, start-up, early, middle, expansion, late stage, mergers and acquisitions investments for industry consolidation.  Hongtai Capital typically invests in relaxation entertainment, media, culture, education, cultural sports, technology, mobile internet, network security, smart hardware, telecommunication, consumer, online consumer, food, beverage, leisure, environmental protection, mobile agriculture, environment-friendly new materials, creativity, chain-style business, retail, , and sensor technology, finance, internet finance, mobile internet products overturning industry models, new consumer, new technology, new finance, and new education sectors. It invests in non-listed companies and in companies listed in the new third board. It seeks to invest in Silicon Valley and Boston, U.S.A.  Hongtai Capital typically invests CNY 0.5 million (USD 74,903.00) to CNY 500 million (USD 81.61 million) per portfolio company. It prefers to invest in companies with a maximum valuation of USD 100 million.  Sheng Taisheng and Yu Minhong founded Hongtai Capital on November 26, 2014. It has its headquarters in Beijing in China.

Hongtai Capital Holdings

TriWise Capital is an investment firm that focuses on venture capital and M&A business.

TriWise Capital

Hefu Ruitai

Lucky Source Funds is an equity investment firm focuses on biomedical health.

Lucky Source Funds

Jiayin Investment specialises in equity investment in companies to be listed.

Jiayin Investment

Knight Capital is a strategic investor in enterprise software companies in North West Europe. Founded by former entrepreneurs, we partner with founders to grow their businesses to a meaningful size and exit within 4-6 years. We focus on companies in niche markets that build great products loved by their customers. Knight Capital was founded in 2019 and is headquartered in Amsterdam, The Netherlands.

Knight Capital

Shenzhen Kaiding Juncan venture Cci Capital is an investment management firm.

Shenzhen Kaiding Juncan venture Cci Capital

Qyuns Therapeutics

Qyuns is developing six candidates, most of them interleukin antibodies. It has two biosimilar drugs in China clinical trials, including a biosimilar to tocilizumab, a Chugai drug marketed as Actemra for various rheumatoid arthritis conditions.

Qyuns Therapeutics is a biopharmaceutical company focused on developing antibody drugs targeting autoimmune and allergic diseases. The company's primary focus is on creating a series of drug candidates aimed at addressing these specific medical conditions. Qyuns aims to leverage its pipeline drugs through strategic partnerships and collaborations to maximize their commercial potential. The company's business model includes exploring opportunities for cooperative development with partners who have resources or advantages in the autoimmune and allergic disease fields. Additionally, Qyuns is open to authorizing its pipeline drugs, either in whole or by region or indication, to partners to enhance the accessibility of its drug candidates in an efficient and cost-effective manner.

Hong Kong stocks edge up, driven by corporate earnings but caution prevails as monetary policy moves eyed

Qyuns Therapeutics Co., Ltd.

Bringing Life-Saving Biologics to More Patients

Biosimilars

QYUNS THERAPEUTICS CO LTD Financial Statements – HKEX:2509 – TradingView

Qyuns Therapeutics is a biopharmaceutical company focused on developing antibody drugs targeting autoimmune and allergic diseases. The company's primary focus is on creating a series of drug candidates aimed at addressing these specific medical conditions. Qyuns aims to leverage its pipeline drugs through strategic partnerships and collaborations to maximize their commercial potential. The company's business model includes exploring opportunities for cooperative development with partners who have resources or advantages in the autoimmune and allergic disease fields. Additionally, Qyuns is open to authorizing its pipeline drugs, either in whole or by region or indication, to partners to enhance the accessibility of its drug candidates in an efficient and cost-effective manner.
Key customers and partnerships
Qyuns Therapeutics seeks collaborations with potential partners interested in entering the autoimmune and allergic disease markets. The company aims to work with partners who possess relevant resources or advantages to jointly develop drug candidates, expand indications, and promote commercialization.

Coherus BioSciences is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immunotherapies for cancer treatment. The company's strategy revolves around building a leading immuno-oncology franchise funded by cash generated from its portfolio of FDA-approved therapeutics. Coherus markets several biosimilar products in the US, including UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, CIMERLI (ranibizumab-eqrn), a biosimilar of Lucentis, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.
In July 2023, Coherus launched YUSIMRY at a list price of USD 995 per carton for two 40 mg/0.8 mL autoinjectors, representing a discount of more than 85% compared to Humira. This pricing strategy aims to improve patient access to adalimumab treatment by offering significant cost savings. YUSIMRY is indicated for various autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease.
Coherus is also developing toripalimab, an anti-PD-1 antibody, for the US and Canadian markets through a licensing agreement with Shanghai Junshi Biosciences Ltd. A Biologics License Application (BLA) for toripalimab in combination with chemotherapy for treating recurrent or metastatic nasopharyngeal carcinoma was under FDA review.
In March 2024, Coherus reported net revenue of USD 91.5 million for Q4 2023 and USD 257.2 million for the full year 2023, driven by sales of UDENYCA and CIMERLI. However, the company faced challenges, including a net loss of USD 79.7 million in Q4 and USD 237.9 million for the full year 2023. To address these challenges, Coherus initiated a workforce reduction of 30% to streamline operations and focus on oncology.

Coherus Biosciences

Custom Biologics is a Canadian contract research organization (CRO) specializing in bioanalytical services for biopharmaceuticals, vaccines, and cell and gene therapy products. With over 20 years of experience, the company focuses on designing and validating regulatory compliant assays for functional characterization, potency/bioactivity assessments, clinical pharmacokinetics, and immunogenicity of biotherapeutic drugs. Custom Biologics' genomics group develops molecular genetic assays for gene and genome analysis, measuring genetic inserts and transgenes in gene therapy vectors, oncolytic viruses, and nucleic acid-based vaccines. The company has also developed a proprietary isothermal nucleic acid amplification technology called DASL-RAPID for rapid identification of human and food-borne pathogens. Custom Biologics maintains a Health Canada cGMP Drug Establishment License and operates under a quality system based on FDA and EMEA GLP guidelines. The company's services are utilized in preclinical research and development programs, as well as for validated GMP-compliant assays suitable for stability analysis, clinical analysis, and clinical/market lot release testing. Custom Biologics employs state-of-the-art bioanalytical laboratory equipment and sophisticated statistical software to generate data for submissions to regulatory agencies worldwide.

Custom Biologics

CuriRx, Inc., founded in 2012, is a contract development and manufacturing organization (CDMO) based in Wilmington, Massachusetts. The company specializes in providing end-to-end support for biotherapeutic drug developers, focusing on complex molecules such as recombinant proteins, monoclonal antibodies, bispecific antibodies, vaccines, antibody drug conjugates, oligonucleotides, and gene therapy products. CuriRx's services encompass upstream and downstream process development, optimization, characterization, scale-up and scale-down, analytical development, formulation development, and lyophilization.
In January 2022, CuriRx launched its Advanced Bioprocessing and Analytical Center, which combines state-of-the-art bioprocessing laboratories with the CuriLytics Platform's high-resolution analytical instrumentation. This center aims to accelerate biotherapeutic drug development by leveraging the team's extensive bioprocessing experience and employing the latest methods in upstream and downstream process development. The CuriLytics Platform utilizes high-resolution mass spectrometry and various orthogonal characterization methods to further de-risk drug development.
CuriRx has the capacity to produce non-GMP vials for animal studies and non-GMP stability support studies. The company's key personnel have been involved in successful development projects for notable drugs such as HUMIRA, SYNAGIS, BLINCYTO, and GATTEX. In September 2013, CuriRx was awarded a five-year contract by the National Cancer Institute for the development and production of oncology products, demonstrating its expertise in the field.

CuriRx

Paras Biopharmaceuticals Finland Oy is a biopharmaceutical technology development company based in Oulu, Finland. Founded in 2012, the company specializes in the development and manufacturing of complex biologics and biosimilars using microbial expression systems. Paras Biopharmaceuticals operates a state-of-the-art 25,000 square foot biologics production facility in Finland, which includes 4,300 square feet of classified cleanroom space. The facility is equipped for media and buffer preparation, fermentation, harvest and extraction, purification, final filtration, and freeze-drying.
The company's core activities are divided into two main divisions: Paras Biopharma, which focuses on biologics Contract Development and Manufacturing Organization (CDMO) services, and Paras Biologics, which handles biosimilar development and licensing. Paras Biopharmaceuticals has developed proprietary technology platforms including Biomultifold, Noblecleav, and Cytofold StructQuant to achieve high productivity and quality in biologics manufacturing. These technologies enable the company to produce complex proteins and biosimilars cost-effectively at scale.
As of December 2022, Paras Biopharmaceuticals reported achieving success with "Continuous Biomanufacturing" for high-value onco-immunology and urology biosimilars. The company has also made advancements in maximizing recombinant protein expression in microbial systems, reporting expression levels of up to 12g/L or more of fully folded, biologically active protein in fermentation broth as of July 2023.

Paras Biopharmaceuticals

Kashiv Biosciences, LLC is a fully integrated biopharmaceutical company focused on developing biosimilars and specialty biopharmaceutical products. The company has global research and development, clinical, regulatory, and manufacturing capabilities. Kashiv utilizes its MayaBio reactor technology to develop biosimilars. The company's product portfolio includes biosimilars targeting conditions such as asthma, chronic idiopathic urticaria, and neutropenia. Kashiv's lead biosimilar candidate, ADL018, is a proposed biosimilar to Xolair (omalizumab) currently in Phase III clinical trials for chronic spontaneous urticaria. In March 2022, Kashiv received FDA approval for its first biosimilar RELEUKO (filgrastim-ayow), a biosimilar referencing Neupogen. The company has a robust pipeline of seven biosimilars and multiple 505(b)(2) and complex peptide generic products in development. Kashiv operates FDA-approved GMP manufacturing facilities in Chicago, Illinois and has state-of-the-art R&D infrastructure in Ahmedabad, India. The company is headquartered in Piscataway, New Jersey.
Key customers and partnerships
Kashiv has established strategic partnerships to commercialize its products globally. In October 2023, Kashiv entered into an exclusive licensing agreement with Alvotech for the development and commercialization of ADL018 in Europe, the UK, Australia, Canada, and New Zealand. In July 2024, Kashiv signed an exclusive licensing agreement with Amneal Pharmaceuticals for the commercialization of ADL018 in the US. Kashiv has also collaborated with Amneal on the development and commercialization of other biosimilars, including RELEUKO and FYLNETRA. These partnerships allow Kashiv to leverage its partners' commercial expertise and global reach to bring its biosimilar products to market.

Kashiv Biosciences

Biotechnology companies that focus on the research, development, production, and commercialization of prescription drugs including biosimilars.

Biotechnology companies that focus on the research, development, production, and commercialization of biosimilars based on original biological medicine.

Companies offering R&D capabilities and production facilities to biosimilar companies on contracts or partnerships.

Biopharmaceutical technology development and support service companies that offer specialized solutions to biosimilar companies.

Companies offering testing solutions to support the biological characterization, comparability, and other clinical assessments required in the biosimilar development process.

AI/ML-driven technology platforms support drug design and development process and integration of drug substance development

Qyuns Therapeutics

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless